6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Serious O
skin B-OSE_Labeled_AE
and O
hypersensitivity O
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Neuropsychiatric B-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reaction O
( O
incidence O
> O
2 O
% O
) O
is O
diarrhea O
( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
BioCryst O
Pharmaceuticals O
, O
Inc O
. O
at O
1-844-273-2327 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
five O
randomized O
, O
double-blind O
, O
controlled O
trials O
, O
1,399 O
subjects O
with O
acute O
uncomplicated O
influenza B-Not_AE_Candidate
received O
a O
single O
dose O
of O
RAPIVAB O
, O
administered O
intravenously O
or O
intramuscularly O
, O
at O
doses O
up O
to O
600 O
mg O
. O

Among O
the O
664 O
subjects O
receiving O
RAPIVAB O
600 O
mg O
( O
intravenous O
or O
intramuscular O
) O
, O
the O
most O
commonly O
observed O
adverse O
reaction O
was O
diarrhea B-OSE_Labeled_AE
, O
occurring O
at O
a O
rate O
of O
8 O
% O
versus O
7 O
% O
in O
subjects O
receiving O
placebo O
. O

No O
subject O
receiving O
RAPIVAB O
600 O
mg O
experienced O
a O
serious O
adverse O
event O
and O
less O
than O
1 O
% O
discontinued O
study O
because O
of O
an O
adverse O
reaction O
. O

Clinically O
significant O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
DAIDS O
Grade O
2-4 O
) O
listed O
in O
Table O
2 O
occurred O
more O
frequently O
in O
subjects O
treated O
with O
RAPIVAB O
600 O
mg O
( O
intravenous O
or O
intramuscular O
) O
than O
placebo O
. O

Only O
events O
occurring O
at O
> O
=2 O
% O
are O
included O
. O

Table O
2 O
: O
Laboratory O
Abnormalities O
Occurring O
in O
> O
=2 O
% O
of O
Subjects O
Treated O
with O
RAPIVAB O
600 O
mg O
Laboratory O
Parameter O
Abnormality O
RAPIVAB O
600 O
mg O
Placebo O
Alanine B-OSE_Labeled_AE
Aminotransferase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
) O
( O
N=654 O
) O
3 O
% O
( O
N=430 O
) O
2 O
% O
Serum B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
( O
N=660 O
) O
5 O
% O
( O
N=433 O
) O
3 O
% O
Creatine B-OSE_Labeled_AE
Phosphokinase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
) O
( O
N=654 O
) O
4 O
% O
( O
N=431 O
) O
2 O
% O
Neutrophils B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
) O
( O
N=654 O
) O
8 O
% O
( O
N=430 O
) O
6 O
% O
In O
a O
subset O
of O
subjects O
with O
serious O
influenza B-Not_AE_Candidate
requiring O
hospitalization O
treated O
with O
RAPIVAB O
600 O
mg O
as O
monotherapy O
( O
N=101 O
) O
the O
following O
adverse O
reactions O
were O
also O
reported O
more O
frequently O
with O
RAPIVAB O
as O
compared O
to O
placebo O
: O
constipation B-OSE_Labeled_AE
( O
4 O
% O
versus O
2 O
% O
) O
, O
insomnia B-OSE_Labeled_AE
( O
3 O
% O
versus O
0 O
% O
) O
, O
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
3 O
% O
versus O
2 O
% O
) O
, O
and O
hypertension B-OSE_Labeled_AE
( O
2 O
% O
versus O
0 O
% O
) O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
RAPIVAB O
in O
Japan O
. O

Because O
postmarketing O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Dermatologic B-NonOSE_AE
: O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
Psychiatric B-NonOSE_AE
: O
abnormal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
, O
hallucination B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O

